



Abnormal Liver Function Test in Patients Infected with
Coronavirus (SARS-CoV-2): A Retrospective Single-Center
Study from Spain
Raquel Benedé-Ubieto 1,2,† , Olga Estévez-Vázquez 1,2,† , Vicente Flores-Perojo 3,
Ricardo U. Macías-Rodríguez 4 , Astrid Ruiz-Margáin 4 , Eduardo Martínez-Naves 1,5, José R. Regueiro 1,5 ,
Matías A. Ávila 6,7,8 , Christian Trautwein 9, Rafael Bañares 8,10, Jaume Bosch 8,11,12 ,





V.; Macías-Rodríguez, R.U.; Ruiz-
Margáin, A.; Martínez-Naves, E.;
Regueiro, J.R.; Ávila, M.A.; Trautwein,
C.; Bañares, R.; et al. Abnormal Liver
Function Test in Patients Infected
with Coronavirus (SARS-CoV-2): A
Retrospective Single-Center Study
from Spain. J. Clin. Med. 2021, 10,
1039. https://doi.org/10.3390/
jcm10051039
Received: 6 January 2021
Accepted: 23 February 2021
Published: 3 March 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine,
28040 Madrid, Spain; rabenede@ucm.es (R.B.-U.); olgaeste@ucm.es (O.E.-V.); emnaves@ucm.es (E.M.-N.);
regueiro@ucm.es (J.R.R.)
2 Department of Genetics, Physiology and Microbiology, Faculty of Biology, Complutense University,
28040 Madrid, Spain
3 iBroker Global Markets, SV, SA, 28033 Madrid, Spain; vicente@ibroker.com
4 Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Mexico City 14080, Mexico; ricardomacro@yahoo.com.mx (R.U.M.-R.); ruizm.astrid@gmail.com (A.R.-M.)
5 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
6 Hepatology Program, CIMA, University of Navarra, 31009 Pamplona, Spain; maavila@unav.es
7 Instituto de Investigaciones Sanitarias de Navarra IdiSNA, 31008 Pamplona, Spain
8 CIBERehd, Instituto de Salud Carlos III, 28220 Madrid, Spain; rafael.banares@salud.madrid.org (R.B.);
jaume.bosch@idibaps.org (J.B.)
9 Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany;
ctrautwein@ukaachen.de
10 Health Research Institute Gregorio Marañón (IiSGM), 28007 Madrid, Spain
11 Barcelona Hepatic Haemodynamic Laboratory, Liver Unit, Institute of Digestive and Metabolic Diseases,
August Pi I Sunyer Institute of Biomedical Research, Hospital Clinic, 08036 Barcelona, Spain
12 Inselspital, Bern University, 3010 Bern, Switzerland
* Correspondence: fcubero@ucm.es (F.J.C.); yulianev@ucm.es (Y.A.N.);
Tel.: +34-91394-1385 (F.J.C.); Fax: +34-913941641 (F.J.C.)
† Contributed equally as first authors.
‡ Contributed equally as senior authors.
Abstract: The outbreak of the novel coronavirus SARS-CoV-2 epidemic has rapidly spread and still
poses a serious threat to healthcare systems worldwide. In the present study, electronic medical
records containing clinical indicators related to liver injury in 799 COVID-19-confirmed patients
admitted to a hospital in Madrid (Spain) were extracted and analyzed. Correlation between liver
injury and disease outcome was also evaluated. Serum levels of Alanine aminotransferase (ALT),
Aspartate aminotransferase (AST), Gamma-glutamyltransferase (GGT), Alkaline phosphatase (ALP),
Lactate dehydrogenase (LDH) and AST/ALT ratio were elevated above the Upper Limit of Normal
(ULN) in 25.73%, 49.17%, 34.62%, 24.21%, 55.84% and 75% of patients, respectively. Interestingly,
significant positive correlation between LDH levels and the AST/ALT ratio with disease outcome
was found. Our data showed that SARS-CoV-2 virus infection leads to mild, but significant changes
in serum markers of liver injury. The upregulated LDH levels as well as AST/ALT ratios upon
admission may be used as additional diagnostic characteristic for COVID-19 patients.
Keywords: SARS-CoV-2; liver injury; pandemic; AST/ALT ratio; ferritin
1. Introduction
The outbreak of a novel enveloped RNA β coronavirus, named severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), is a major challenge for health systems worldwide
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from the beginning of 2020. As a result of its rampant spread and clinical severity, the
World Health Organization (WHO) officially recognized the coronavirus disease (COVID-
19) as a pandemic on 11 March, 2020. By February 2021, the virus had already infected
over 114 million people worldwide, causing more than 2.5 millions deaths and at least
69,142 deaths in Spain alone.
A remarkable amount of clinical studies were published in order to elucidate the
clinical manifestations of SARS-CoV-2 infection. Apart from asymptomatic or paucisymp-
tomatic forms, and severe viral pneumonia with respiratory failure, COVID-19 disease prog-
nosis is influenced by indirect effects on body-wide organs via the angiotensin-converting
enzyme-2 (ACE-2) receptor, including heart and renal failure, damage to the central nervous
system (CNS) and to the gastrointestinal tract [1,2].
Specifically, in the liver, the effect of COVID-19 has been evaluated in relatively few
studies, which focused on alterations in liver histopathology and biochemistry during the
course of infection in patients who succumbed to the virus [3–8]. Several up-to-date studies
have attempted to evaluate parameters related to liver injury in American and Asian
cohorts [3,8–11], as well as in European cohorts [12–15]. Yet liver disease in the context of
SARS-CoV-2 infection remains largely unknown, thus minimizing the understanding of
abnormal liver function in terms of the overall outcome.
Therefore, we performed a retrospective single-center analysis of laboratory indicators
of liver injury upon admission in a large cohort of COVID-19-confirmed patients admitted
to the Hospital Universitario 12 de Octubre in Madrid (Spain) during the current outbreak.
2. Materials and Methods
2.1. Study Design and Patients
This retrospective single-center study was performed from 25 February 2020 to
23 April 2020 in patients admitted to the Hospital Universitario 12 de Octubre in Madrid.
A total of 799 were confirmed cases of SARS-Cov-2. Demographic and clinical parameters
of interest were collected from electronic medical records (Table 1). Patients were followed-
up until death, hospital discharge or the end of the observation period (23 April 2020).
Personal data complied with the Law 14/2007 of 3 July on Biomedical Research (Spain),
as well as the EU general data protection regulation (GDPR) 2016/679 of the European
Parliament and of the Council of 27 April 2016, and the Organic Law 3/2018, of 5 December
on Data Protection and Guarantee of Digital Rights (Spain).
Confirmed diagnosis of SARS-CoV-2 was based on a positive quantitative real-time
(RT) reverse transcriptase PCR (qRT-PCR) assay performed on oropharyngeal swab (Ther-
mofisher TaqPath™ 1-Step RT-qPCR Master Mix, CG).
Clinical characteristics data included oxygen saturation levels (SO2) by pulse oximetry
(%) and blood chemical analyses which were routinely measured using standard methods
on the first day of hospitalization before administration of any therapy. Laboratory eval-
uations consisted of alanine aminotransferase (ALT), aspartate aminotransferase (AST),
gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP) and lactate dehydrogenase
(LDH), ferritin, fibrinogen, prothrombin time (PT (s)) and D-dimers (DD).
Abnormality in test parameters was defined as the elevation of ALT > 41 U/L, AST >
38 U/L, GGT > 58 U/L, ALP > 96 U/L, LDH > 333 U/L, ferritin> 200 ng/mL for women
and > 500 ng/mL for men, fibrinogen > 400 mg/dL, PT > 14s, DD > 250 µg/L and SO2
level < 90%.
2.2. Statistical Analysis
Analyses were performed using IBM SPSS v25 (IBM Corp. Armonk, NY, USA). Data
were expressed as means ± standard deviation (SD). Comparisons between groups were
performed using T-test for independent samples. p-values for significance are indicated as
follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. Distribution plots and correlations were ana-
lyzed. The relation between liver function tests (LFTs) and variables such as age, SO2 and
coagulation parameters were analyzed. Recently were considered as dependent variables,
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while the rest were considered as independent or predictor variables. Independent and
dependent variables were correlated using lineal regression. Correlation coefficient (R2)
and cases (%) represented were studied in detail.
Multivariant analysis between LFTs, age, gender and outcome was performed. Inter-
actions between those independent factors and LFTs were analyzed in detail via two-way
analysis of variance (ANOVA) two-way. p-value (p < 0.05) indicated real interaction be-
tween determined factors for each LFTs marker.
3. Results
Of all participants enrolled in this study, 362 (45.3%) were women and 437 (54.7%) were
men (Table 1). Patients were predominantly middle-aged with a mean age of 64.11 ± 16.92
years of age. Of the 799 patients, 140 (17.5%) patients died and 659 (82.5%) survived
(Table 1).
Table 1. Characteristics of 799 patients infected with SARS-CoV-2, including demography and
outcome, extracted from the electronic medical records.
Characteristics




Age, years, n (%)
<19, n (%) 2 (0.3%)
20–29, n (%) 21 (2.6%)
30–39, n (%) 45 (5.6%)
40–49, n (%) 100 (12.5%)
50–59, n (%) 177 (22.2%)
60–69, n (%) 143 (17.9%)
70–79, n (%) 147 (18.4%)
80–89, n (%) 139 (17.4%)




For most of the 799 patients, mean values for liver tests (LT) were normal as indicated
by levels of ALT (38.07 ± 39.61 U/L), AST (43.57 ± 35.35 U/L), GGT (69.42 ± 85.11 U/L),
ALP (87.32 ± 67.91 U/L) or slightly increased in the case of LDH (369.58 ± 159.08 U/L)
(Table 2). Elevated ALT, AST, GGT and ALP levels were detected in 25.73%, 49.17%,
34.62% and 24.21% of patients, respectively. Interestingly, LDH levels were raised in 55.8%
of patients.
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Table 2. Clinical characteristics of 799 patients with confirmed COVID-19, including gender differences, age and outcome of
disease in connection to biomarkers of liver injury.
PARAMETERS ALT AST GGT ALP LDH AST/ALTRatio
Total, X ± SD
(U/L)



























35.55 ± 2.39 41.67 ± 1.83 61.57 ± 4.59 88.59 ± 3.16 363.85 ± 8.90 1.46 ± 0.39
Men, X ± SD
(U/L)




X ± SD (U/L)
AST
X ± SD (U/L)
GGT
X ± SD (U/L)
ALP
X ± SD (U/L)
LDH
X ± SD (U/L)
AST/ALT
Ratio
<19 251.500 ±222.50 153.50 ± 114.50 272.50 ± 205.50 547.50 ± 140.50 838.50 ± 564.00 0.96 ± 0.39
20–29 47.95 ± 7.10 40.47 ± 4.71 68.74 ± 14.72 94.68 ± 12.62 311.37 ± 23.90 0.98 ± 0.09
30–39 52.20 ± 6.99 43.90 ± 4.72 82.63 ± 16.78 82.60 ± 6.99 307.88 ± 16.68 1.04 ± 0.07
40–49 46.21 ± 4.46 43.38 ± 4.28 78.65 ± 9.54 102.69 ± 13.34 342.90 ± 13.42 1.06 ± 0.04
50–59 45.54 ± 3.46 49.58 ± 3.81 84.13 ± 8.23 90.43 ± 4.52 382.29 ± 12.71 1.22 ± 0.03
60–69 35.54 ± 2.38 41.23 ± 1.96 74.64 ± 7.24 77.34 ± 4.22 345.32 ± 11.27 1.30 ± 0.04
70–79 30.17 ± 1.86 42.20 ± 2.37 60.95 ± 5.67 83.63 ± 5.25 394.28 ± 14.48 1.30 ± 0.04
80–89 29.46 ± 3.71 41.79 ± 3.18 51.91 ± 6.54 85.15 ± 5.09 380.51 ± 16.22 1.87 ± 0.15
90–99 19.50 ± 1.92 35.63 ± 3.77 36.69 ± 7.32 76.88 ± 5.27 349.84 ± 19.47 2.05 ± 0.14
OUTCOME ALTX ± SD (U/L)
AST
X ± SD (U/L)
GGT
X ± SD (U/L)
ALP
X ± SD (U/L)
LDH
X ± SD (U/L)
AST/ALT
Ratio
Dead 33.59 ± 3.88 51.51 ± 4.71 64.43 ± 6.87 91.53 ± 5.97 439.72 ± 19.17 1.80 ± 0.07
Survived 38.88 ± 1.60 42.24 ± 1.29 70.80 ± 3.56 86.31 ± 2.77 352.73 ± 5.72 1.33 ± 0.04
ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; ALP, alkaline
phosphatase; LDH, lactate dehydrogenase.
In most patients, elevations of liver parameters were within 2× the upper limit
of normal (ULN) (Table 2 and Figure 1A–E). For example, 362 patients had LDH within
2 × ULN, 34 within 2–3 ULN and only 4 above 3 × ULN (Figure 1E). Moreover, the majority
of patients (75%) had higher AST than ALT values, with a De Ritis ratio (AST/ALT) of
1.41 ± 0.91 (Table 2 and Figure 1F).
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Figure 1. Liver function tests (LFTs) in patients with COVID-19 at admission. Number of patients within and above the 
upper limits of normal (ULN) for (A) ALT, (B) AST, (C) GGT, (D) ALP, (E) LDH and (F) AST/ALT ratio. 
Men presented higher level of GGT (Figure 2C); women had higher De Ritis ratio 
levels (Figure 2F). However, ALT, AST, ALP and LDH values did not show any 
difference due to gender (Figure 2). 
Figure 1. Liver fu ction tests (LFTs) in patien s with COVID-19 at admission. Number of patients within and above the
upper limits of normal (ULN) for (A) ALT, (B) AST, (C) GGT, (D) ALP, (E) LDH and (F) AST/ALT ratio.
Men pr sented higher level of GGT (Figure 2C); women ad higher De Ritis ratio
levels (Figure 2F). How ver, ALT, AST, and LDH values did not show any difference
due to g nder (Figure 2).
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Figure 2. Gender influence on LFTs changes in COVID-19 positive patients at admission. Serum levels of (A) ALT. Women
= 35.55 ± 2.39; men = 40.04 ± 1.85 (B) AST. Women = 41.67 ± 1.83; men = 45.53 ± 1.91 (C) GGT. Women = 61.57 ± 4.59;
men = 76.53 ± 4.37 (D) ALP. Women = 88.59 ± 3.16; men = 86.00 ± 3.79 (E) LDH. Women = 363.85 ± 8.9; men = 369.88
± 7.77 and (F) AST/ALT. Women = 1.65 ± 0.36; men = 1.55 ± 0.69. Ratios in women (light grey) and men (dark grey);
(**-* p < 0.01–0.05).
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The correlations between age of the patient and serum markers of liver injury were
mild (Table 2 and Figure 3A–E). Only AST/ALT ratio had a significant positive correla-
tion with age in 32.9% of cases and on average was 1.87–2.05 in patients over 80 years
(Tables 2 and 3 and Figure 3F).
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Figure 3. Correlation between liver biochemical parameters at admission and age in COVID-19-confirmed patients. (A) 
ALT; Pearson coefficient = −0.234; F value = 45.973; p < 0.0001. (B) AST; Pearson coefficient = −0.072; F value = 3.994; p = 
0.046. (C) GGT; Pearson coefficient = −0.051: F value = 18.270; p < 0.0001. (D) ALP; Pearson coefficient = −0.088; F value = 
5.584; p = 0.016. (E) LDH; Pearson coefficient = 0.073; F value = 4.416; p = 0.042. (F) AST/ALT ratio; Pearson coefficient = 
0.329; F value = 93.633; p < 0.0001. R2 calculations appear on the upper right side of each graph. Age interval, 10 years. 
i ure 3. Co relation between liver biochemical parameters t admissio and age in COVID-19-confirmed patients. (A) ALT;
Pearson coefficient = −0.234; F value = 45.973; p < 0.0 1. ( ) ; rson coefficient = −0.072; F value = 3.994; p = 0.046.
(C) GGT; Pearson coefficient = −0.051: F value = 18.270; p < 0.0001. (D) ALP; Pearson coefficient = −0.088; F value = 5.584;
p = 0.016. (E) LDH; Pearson coefficient = 0.073; F value = 4.416; p = 0.042. (F) AST/ALT ratio; Pearson coefficient = 0.329;
F value = 93.633; p < 0.0001. R2 calculations appear on the upper right side of each graph. Age interval, 10 years.
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Table 3. Lineal correlation between liver tests and age.










ALT −0.234 * 0.055 0.234 0.0001 23.4%
AST −0.072 * 0.005 0.072 0.046 7.2%
GGT −0.151 * 0.023 0.151 0.0001 15.1%
ALP −0.088 * 0.008 0.088 0.016 8.8%
LDH 0.073 † 0.005 0.073 0.042 7.3%
AST/ALT 0.329 † 0.108 0.329 0.0001 32.9%
Pearson coefficient, R2 value, R and p value related to correlation (calculated though ANOVA) are indicated.
% of cases represented by each paired correlation is shown. Negative correlations are labeled with *. Positive
correlations are marked with †.
Additionally, we compared liver parameters between COVID-19 survivors and non-
survivors (Table 2). No obvious difference was found in ALT, GGT and ALP levels between
COVID19 survivors and non-survivors (Table 2 and Figure 4A–D). Remarkably, levels of
AST and LDH were higher in patients with bad prognosis versus patients who survived:
51.51 ± 4.71 vs. 42.24 ± 1.29 and 439.72 ± 19.17 vs. 352.73 ± 5.72, respectively (Table 2
and Figure 4E). Interestingly, patients who died had significantly higher AST/ALT ratios
upon admission when compared with patients who survived (1.80 ± 0.69 vs. 1.33 ± 0.36)
(Figure 4F).
Clinical characteristics of the patients and LFTs were included in the multivariate
analysis (Supplementary Table S1), which showed that gender, survival and age were
significantly associated with AST and LDH; and only gender and survival had significant
interaction with AST/ALT ratio.
In patients with severe COVID-19, pneumonia, respiratory failure, systemic inflam-
mation and thrombotic complications are the most frequent [16]. Therefore, next we
investigated whether AST, LDH levels and De Ritis ratio correlate with disease sever-
ity. We analyzed these three liver-related parameters which were mainly upregulated
in our patients and compared them with laboratory markers associated with COVID-19
complications.
COVID-19 primarily attacks the respiratory system leading to pneumonia and oxygen
deprivation [17]. Hence, upon admission only 7% of patients demonstrated signs of
hypoxia with oxygen saturation (SO2) level <90%. No significant correlation between SO2
and liver-related parameters was found in our study (Tables 3 and 4 and Figure 5A–C).
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Figure 4. Disease outcome for COVID-19 patients based on LFTs parameters at admission. (A) ALT. Dead = 33.58 ± 3.88;
survived = 38.88 ± 1.60 (B) AST. Dead = 51.51 ± 4.71; survived = 42.24 ± 1.29 (C) GGT. Dead = 64.43 ± 6.87; survived =
70.80 ± 3.56 (D) ALP. Dead = 91.53 ± 5.98; survived = 86.31 ± 2.77 (E) LDH. Dead = 439.73 ± 19.17; survived = 352.73 ± 5.72
and (F) AST/ALT. Dead = 1.80 ± 0.79; survived = 1.33 ± 0.91. Ratio was calculated and divided between non-survivors
(deceased, black) and survivors (white); (**** p < 0.0001).
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Figure 5. The correlation between biochemical LFTs with SO2 and ferritin, and main coagulogram parameters in COVID
−19 patients. (A) AST and SO2; Pearson coefficient = −0.072; F value = 3.723; p = 0.054. (B) LDH and SO2; Pearson
coefficient = −0.228; F value = 38.924; p < 0.0001. (C) AST/ALT ratio and SO2; Pearson coefficient = −0.106; F value = 8.087;
p < 0.005. (D) AST and ferritin; Pearson coefficient = 0.434; F value = 121.577; p < 0.0001. (E) LDH and ferritin; Pearson
coefficient = 0.357; F value = 75.464; p < 0.0001. (F) AST/ALT ratio and ferritin; Pearson coefficient = −0.079; F value = 3.245;
p = 0.072. R2 calculations appear on the upper right side of each graph.
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Table 4. Laboratory findings of COVID-19-positive patients on admission to hospital.
PARAMETERS SO2 FERRITIN FIBRINOGEN PT Time D Dimers
Total, X ± SD 95.45 ± 4.18% 1145.05 ± 1222.16ng/mL
733.34 ± 209.13

















Women, X ± SD (U/L) 95.75 ± 0.21% 804.43 ± 53.69ng/mL
695.63 ± 11.52
mg/dL 18.24 ± 3.33 s 3420.64 ± 850.14 µg/L
Men, X ± SD (U/L) 95.19 ± 0.22% 1439.87 ± 82.57ng/mL
763.25 ± 12.21
mg/dL 16.97 ± 1.77 s 2958.69 ± 791.39 µg/L
AGE
(years) SO2 (%) FERRITIN (ng/mL)
FIBRINOGEN
(mg/dL) PT Time (s) D Dimers (µg/L)
<19 95.50 ± 1.50 916.00 ± 823.00 537.00 ± 282.00 11.55 ± 0.05 3478.50 ± 2576.50
20–29 97.95 ± 0.41 734.20 ± 149.93 732.83 ± 70.06 12.96 ± 0.46 792.60 ± 140.35
30–39 96.97 ± 0.37 769.73 ± 209.10 634.26 ± 24.75 12.87 ± 0.17 470.63 ± 51.25
40–49 96.36 ± 0.30 1091.15 ± 165.12 784.40 ± 25.83 13.13 ± 0.14 1077.98 ± 451.12
50–59 96.24 ± 0.25 1309.02 ± 137.48 750.78 ± 17.60 13.44 ± 0.21 1515.38 ± 411.47
60–69 95.48 ± 0.33 1308.92 ± 111.77 766.80 ± 15.92 13.76 ± 0.41 3925.34 ± 1648.36
70–79 94.47 ± 0.41 1204.33 ± 100.18 749.51 ± 25.53 28.20 ± 9.19 5487.67 ± 2311.68
80–89 94.24 ± 0.44 903.75 ± 112.01 676.24 ± 15.96 19.84 ± 2.14 4873.30 ± 1719.06
90–99 94.91 ± 1.00 945.79 ± 196.733 664.33 ± 37.80 18.18 ± 1.78 4205.78 ± 1665.44
OUTCOME SO2 (%) FERRITIN (ng/mL)
FIBRINOGEN
(mg/dL) PT Time (s) D Dimers (µg/L)
Dead 92.31 ± 0.57% 1629.05 ± 214.96ng/mL
745.97 ± 19.26
mg/dL 17.54 ± 1.38 s 8082.74 ± 2570.75 µg/L
Survived 96.07 ± 0.13% 1081.26 ± 51.70ng/mL 730.91 ± 9.58 mg/dL 17.54 ± 2.14 s 2285.39 ± 497.74 µg/L
SO2, oxygen saturation; PT, prothrombin.
Several studies reported that COVID-19 patients have elevated levels of ferritin, and
that this marker is strongly associated with the development of systemic inflammation
in COVID-19 patients [18]. Indeed, ferritin was elevated in 81.15% of the patients upon
admission time (Table 3), and was significantly higher in patients with bad prognosis.
However, we found positive correlation between ferritin and AST in 43.3% of the cases;
and between ferritin and LDH in 35.5% of patients (Figure 5D–F and Table 5).
Table 5. Lineal correlation of liver tests to O2 saturation and ferritin.










AST −0.072 * 0.005 0.072 0.054 7.2%
LDH −0.228 * 0.052 0.228 0.0001 22.8%
AST/ALT −0.106 * 0.011 0.106 0.005 10.6%










AST 0.434 † 0.188 0.434 0.0001 43.3%
LDH 0.357 † 0.127 0.357 0.0001 35.7%
AST/ALT −0.079 * 0.006 0.079 0.0001 7.9
Pearson coefficient, R2 value, R and p value related to correlation adjustment (calculated though ANOVA) are
indicated. % of cases represented by each paired correlation is shown. Negative correlations are labeled with *.
Positive correlations are marked with †.
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The coagulopathy accompanying COVID-19 has been associated with extremely
elevated DD and fibrinogen levels as well as modest prolongations of prothrombin time
(PT) [19]. In fact, in our study we found increased fibrinogen in 96.61%, prolongation of PT
time in 69.64% and elevation of DD in 90.98% of the admitted patients (Table 4). Moreover,
DD were dramatically higher (p = 0.016) in patients with bad prognosis versus patients
who survived. However, COVID-associated coagulopathy was relatively weakly correlated
with AST, LDH or De Ritis ratio (Figure 6A–I and Table 6). Such as, in 36.5% of the cases
the LDH level had significant positive correlation with elevated DD, and with fibrinogen
in 15.2% of the cases. AST showed significant correlation with elevated fibrinogen in 10.4%
of the patients (Table 6).
Table 6. Lineal correlation to D-dimers, fibrinogen and PT time to liver tests.










AST 0.076 † 0.006 0.076 0.09 7.6%
LDH 0.365 † 0.133 0.365 0.0001 36.5
AST/ALT 0.041 † 0.002 0.041 0.361 4.1%










AST 0.013 † 0.011 0.104 0.013 10.4%
LDH 0.152 † 0.023 0.152 0.0001 15.2%
AST/ALT −0.116 * 0.014 0.116 0.005 11.6%










AST 0.008 † 0.0001 0.008 0.833 0.8%
LDH 0.035 † 0.001 0.035 0.334 3.5%
AST/ALT 0.053 † 0.003 0.053 0.145 5.3%
Pearson coefficient, R2 value, R and p value related to correlation adjustment (calculated though ANOVA) are
indicated. % of cases represented by each paired correlation is shown. The negative correlations are labeled with
*. Positive correlations are marked with †.
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Figure 6. The correlation between biochemical LFTs and main coagulogram parameters in COVID-19 patients. (A) AST and
DD; Pearson coefficient = 0.076; F value = 2.889; p = 0.09. (B) LDH and DD; Pearson coefficient = 0.365; F value = 74.716;
p < 0.0001. (C) AST/ALT ratio and DD; Pearson coefficient = 0.041; F value = 0.836; p = 0.361. (D) AST and fibrinogen;
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Pearson coefficient = 0.104; F value = 6.243; p = 0.013. (E) LDH and fibrinogen; Pearson coefficient = 0.152; F value = 13.307;
p < 0.0001. (F) AST/ALT ratio and fibrinogen; Pearson coefficient = −0.116; F value = 7.808; p = 0.005. (G) AST and PT time;
Pearson coefficient = 0.008; F value = 0.044; p = 0.833. (H) LDH and PT time; Pearson coefficient = 0.035; F value = 0.934;
p = 0.334. (I) AST/ALT ratio and PT time; Pearson coefficient = 2.131; F value = 6.243; p = 0.143. R2 calculations appear on
the upper right side of each graph.
4. Discussion
To what extent liver damage is relevant to the novel SARS-CoV-2 pandemic remains
still unclear. In the present study, we described clinical characteristics of 799 patients
who were admitted to the Hospital Universitario 12 de Octubre in Madrid (Spain), with
COVID-19 symptoms and who tested positive for COVID-19. We used the values of ALT,
AST, ALP, GGT and LDH as the predominant screening examinations of the functional
status of the liver.
Here we report that upon admission, ALT, GGT and ALP were significantly elevated in
approximately 25–35% of COVID-19-confirmed cases. While 49.17% of patients presented
elevations in AST levels, nearly 56% had increased LDH values. A few previous clinical
studies based on single or multiple centers have already shown that COVID-19 patients
have signs of liver injury [5] (Supplementary Table S1). Concomitant with our findings,
two studies from Wuhan showed that approximately 35–53% of COVID-19 patients had
elevated AST [3,20]. In a larger American cohort that included 5700 patients, 59% and
39% showed AST and ALT values above ULN, respectively [10]. In agreement with our
data, two independent studies from Northern Italy [12] and Austria [15] demonstrated
upregulation of AST in 44% and 42% of admitted patients with SARS-CoV-2, respectively.
In contrast, fewer patients (only 16% and 20%) had abnormal AST levels in the studies from
Zhejiang Province [4] and Rome [13]. The increase in LDH was detected in 27% COVID-
patients of Zhejiang Province [4] and in 73% patients in Wuhan [4,21] (Supplementary
Table S2).
These findings are worth discussing since the SARS-CoV-2 virus should be potentially
regarded as hepatotropic. Angiotensin converting enzyme 2 (ACE2) was identified as a
functional receptor for SARS-CoV-2, and ACE2 expression is high in lung, heart, ileum,
kidney and bladder [2]. However, the expression level of ACE2 in liver tissue was only
approximately 0.31% and the specific expression of ACE2 in bile duct epithelial cells was
20 times higher than that in hepatocytes [22,23]. Thus, potential damage to cholangiocytes
by SARS-CoV-2 may lead to profound and unexpected consequences in the liver. Hence,
despite the presence of ACE2 in cholangiocytes, more patients developed raised levels
of transaminases [23]. On the other hand, there exist wide discrepancies between organ
symptomatology and ACE2 expression levels. For instance, ACE2 expression in the
respiratory tract is only moderate compared with that in intestinal epithelia, but respiratory
symptomatology is substantially more severe than intestinal [24,25].
Nonetheless, pathological analysis of liver tissue from a patient who died from COVID-
19 showed that viral inclusions were not observed in the liver [26]. Any reported [27]
‘spiked’ inclusions and degenerate ‘corona-like’ particles in hepatocytes were not confirmed
by PCR testing for viral nucleic acids [28].
A very likely explanation of the mechanisms leading to liver dysfunction during
COVID-19 refers not to the direct cytopathic effects of the virus, but rather to the generalized
stress due to the multi-organic character of the infection, which is accompanied by immune
injury, systemic inflammatory response syndrome (SIRS) and a stormy release of cytokines
that can cause liver injury per se [23,29,30].
One of the clinical characteristics of COVID-19-derived SIRS is “hyperferritinemic
syndrome” and high serum ferritin level [31]. Indeed, 81% of patients in our study had
elevated levels of ferritin upon admission. Moreover, ferritin levels were significantly
higher in patients who subsequently died. Hence, 43.3% of the patients had significant
positive correlation between levels of ferritin and AST, and 35.7% between ferritin and
LDH levels.
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Another important finding of the present study was the elevated LDH levels found
in patients with COVID-19 infection already at the time of admission, and its positive
correlation with disease outcome. The increase of LDH reflects tissue/cell destruction
and is associated with a wide range of disorders, including liver and lung disease. Inter-
estingly, elevated LDH levels were previously shown to be associated with severe SARS
infection [32]. The pathogenesis of COVID-19 has been also linked with the development
of respiratory failure and hypoxia [2]. Hence there is convincing evidence linking high
LDH levels with severe COVID-19 pneumonia and mortality [33–35]. Moreover, the nor-
malization of serum LDH was consistently accurate in predicting treatment success of the
patients [36].
LDH is an essential enzyme for anaerobic respiration, and its production has also
been shown to be increased under hypoxic conditions in the liver [37]. Therefore, poor
oxygen delivery can lead to hypoxic hepatitis, thus accounting for LDH elevation [38].
Hence, we detected no correlation between LDH and oxygen saturation. Still there is
a consideration that all electronic records were obtained upon admission. Our results
indicate that microcirculation disturbance exists from early stages of the disease and LDH
levels could be regarded as a potential prognostic marker.
The liver is closely related to the synthesis of coagulation factors, which means that
when the liver is damaged, it will directly affect the coagulation process. Furthermore,
coagulation dysfunction in COVID-19 patients may cause liver damage due to thrombosis.
Hence, the exact relationship between COVID-19-induced dysfunction of coagulation and
liver damage is unclear [19,39]. In our study, we found significant positive correlation be-
tween elevated LDH and DD in 36.5% of the cases, as well as between LDH and fibrinogen
in 15.2% of the cases. In 10.4% of the patients, AST showed significant correlation with
elevated fibrinogen.
Another interesting and yet unpublished observation from our current study, was
the significant increase AST/ALT (De Ritis ratio) in 75% of patients. The De Ritis ratio
can also theoretically increase due to a reduction in AST clearance from the blood by the
liver sinusoids [40]. This is supported by the fact that ACE2 occurrence has been also
reported in endothelial cells [41]. However, the elevation of the AST/ALT ratio might also
indicate a non-hepatic source of injury and massive death of non-liver cells, for example
muscle damage [40]. Myalgia is a common symptom in 36% patients with COVID-19 [42].
Nonetheless, myalgia in patients with COVID-19 may be longer in duration than other viral
infections and may be unresponsive to conventional painkillers. In addition to the classic
mechanisms of myalgia known in viral infections, including generalized inflammation
and cytokine response, COVID-19 can directly damage the musculoskeletal system due
to the presence of ACE2 in skeletal muscles [43]. Consistently, viral damage in muscles—
associated with increased LDH levels, in turn, promote an excessive accumulation of
lactate, leading to muscle pain [44]. However, further studies need to confirm the molecular
mechanisms and the cell-specific damage triggering an elevation of the De Ritis ratio.
Altogether, our results indicate that elevations in liver-related parameters are notice-
ably mild. It is tempting to speculate that abnormalities in liver function tests are not caused
by direct SARS-CoV-2 liver injury, but very likely they are a result of “nonspecific reactive
hepatitis”. Indeed, influenza infection as well as many other respiratory viruses produce
similar elevations of liver function biomarkers, which is just a “collateral damage” related
to immune interactions involving intrahepatic cytotoxic T and KCs [21,45]. Moreover, it is
very likely that AST and LDH elevations do not necessarily arise from the liver alone, but
can be also the results of myositis similar to that observed in influenza [21].
Since the liver is involved in drug metabolism, including nucleoside analogues and
protease inhibitors, currently used for the treatment of COVID-19, drug-induced liver
injury (DILI) must be considered during SARS-CoV-2 infection [46]. In our study, we
exclusively used laboratory parameters electronically collected upon admission, in order
to avoid any possible effects related to drug toxicity due to treatment. However, such
effects were observed in many patients [8,13,14], who developed substantial increases in
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ALT and GGT levels during hospitalization Moreover, recent clinical trials using lopinavir
and ritonavir in severe COVID-19 patients reported elevated levels of AST, ALT and total
bilirubin as adverse side effects in a few patients [47]. Additionally, elevated levels of
bilirubin and ALT/AST were also detected in patients treated with Remdesivir [48].
However, our study has several limitations. Although data were collected in a single
center, being a guarantee of their homogeneity, the study was retrospective, and the data
were extracted from electronic documentation. This potentially precluded the detailed
analysis level done with a manual medical record review. Therefore, only the laboratory
characteristics at admission were considered. Still some potential confounders could have
been missing. Thus, we cannot exclude that some patients actually had LFTs abnormalities
due to chronic liver diseases (CLD) before COVID-19. Hence, a recent large international
registry study demonstrated that patients with CLD without cirrhosis appeared to have a
similar risk of mortality following SARS-CoV-2 infection than those without CLD. However,
patients with cirrhosis are at increased risk of death from COVID-19 [49].
Further research is urgently needed, in order to provide new insights in the multi-
systemic effects of SARS-CoV-2 infection focusing on:
(i) Pathophysiological causes of fluctuation in liver injury parameters in COVID-19
patients;
(ii) A more detailed analysis of the effects of existing liver-related comorbidities on the
outcome of the disease, and;
(iii) The potential mechanisms of hepatotoxicity of treatment for COVID-19. Detailed
information from different national registries is particularly important in order to
understand the heterogeneous character of COVID-19 and its real impact on the liver.
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